{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:55:07Z","timestamp":1793307307463,"version":"4.5.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13555-021-00483-2","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T04:42:56Z","timestamp":1611895376000},"page":"385-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities"],"prefix":"10.1007","volume":"11","author":[{"given":"Alan","family":"Menter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yeon","family":"Paek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Kivelevitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iannis E.","family":"Adamopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"issue":"5","key":"483_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496\u2013509.","journal-title":"N Engl J Med"},{"issue":"9997","key":"483_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386(9997):983\u201394.","journal-title":"Lancet"},{"issue":"3","key":"483_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"483_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"483_CR5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","volume":"143","author":"JM Gelfand","year":"2007","unstructured":"Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493\u20139.","journal-title":"Arch Dermatol"},{"key":"483_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG. Immunology of psoriasis. Ann Rev Immunol. 2014;32:227\u201355.","journal-title":"Ann Rev Immunol"},{"issue":"3","key":"483_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645\u201353.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"483_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/jid.2010.374","volume":"131","author":"RA Clark","year":"2011","unstructured":"Clark RA. Gone but not forgotten: lesional memory in psoriatic skin. J Invest Dermatol. 2011;131(2):283\u20135.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"483_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","volume":"38","author":"SK Mahil","year":"2016","unstructured":"Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11\u201327.","journal-title":"Semin Immunopathol"},{"issue":"11","key":"483_CR10","doi-asserted-by":"publisher","first-page":"e79253","DOI":"10.1371\/journal.pone.0079253","volume":"8","author":"WR Swindell","year":"2013","unstructured":"Swindell WR, Johnston A, Xing X, Voorhees JJ, Elder JT, Gudjonsson JE. Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation. PLoS ONE. 2013;8(11):e79253.","journal-title":"PLoS ONE"},{"issue":"7","key":"483_CR11","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/jid.2010.103","volume":"130","author":"BB Davidovici","year":"2010","unstructured":"Davidovici BB, Sattar N, J\u00f6rg PC, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785\u201396.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"483_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41584-019-0285-8","volume":"15","author":"A Bravo","year":"2019","unstructured":"Bravo A, Kavanaugh A. Bedside to bench: defining the immunopathogenesis of psoriatic arthritis. Nat Rev Rheumatol. 2019;15(11):645\u201356.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"483_CR13","doi-asserted-by":"publisher","first-page":"E530","DOI":"10.3390\/ijms19020530","volume":"19","author":"MA Boutet","year":"2018","unstructured":"Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):E530.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"483_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jaad.2018.02.040","volume":"79","author":"B Lockshin","year":"2018","unstructured":"Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018;79(2):345\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"483_CR15","doi-asserted-by":"publisher","first-page":"E179","DOI":"10.3390\/ijms19010179","volume":"19","author":"A Chiricozzi","year":"2018","unstructured":"Chiricozzi A, Romanelli P, Volpe E, Borsellino G, Romanelli M. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018;19(1):E179.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"483_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"483_CR17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jaci.2009.08.046","volume":"124","author":"LC Zaba","year":"2009","unstructured":"Zaba LC, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009;124(5):1022-30.e395.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"483_CR18","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.bbamcr.2011.06.019","volume":"1813","author":"ML Schmitz","year":"2011","unstructured":"Schmitz ML, Weber A, Roxlau T, Gaestel M, Kracht M. Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines. Biochim Biophys Acta. 2011;1813(12):2165\u201375.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"483_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/jid.2010.340","volume":"131","author":"A Chiricozzi","year":"2011","unstructured":"Chiricozzi A, Guttman-Yassky E, Su\u00e1rez-Fari\u00f1as M, Nograles KE, Tian S, Cardinale I, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677\u201387.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"483_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejcb.2014.12.003","volume":"94","author":"F Prignano","year":"2015","unstructured":"Prignano F, Arnaboldi F, Cornaghi L, Landoni F, Tripo L, Preis FW, et al. Tumor necrosis factor-alpha and interleukin-17 differently affects Langerhans cell distribution and activation in an innovative three-dimensional model of normal human skin. Eur J Cell Biol. 2015;94(2):71\u20137.","journal-title":"Eur J Cell Biol"},{"issue":"5","key":"483_CR21","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.4049\/jimmunol.1201505","volume":"190","author":"A Johnston","year":"2013","unstructured":"Johnston A, Fritz Y, Dawes SM, Diaconu D, Al-Attar PM, Guzman AM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252\u201362.","journal-title":"J Immunol"},{"issue":"1","key":"483_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s13238-011-1006-5","volume":"2","author":"X Zhang","year":"2011","unstructured":"Zhang X, Angkasekwinai P, Dong C, Tang H. Structure and function of interleukin-17 family cytokines. Protein Cell. 2011;2(1):26\u201340.","journal-title":"Protein Cell"},{"issue":"11","key":"483_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/exd.12487","volume":"23","author":"RR Keijsers","year":"2014","unstructured":"Keijsers RR, Joosten I, van Erp PE, Koenen HJ, van de Kerkhof PC. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp Dermatol. 2014;23(11):799\u2013803.","journal-title":"Exp Dermatol"},{"issue":"1","key":"483_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4049\/jimmunol.1100123","volume":"187","author":"AM Lin","year":"2011","unstructured":"Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1):490\u2013500.","journal-title":"J Immunol"},{"issue":"5","key":"483_CR25","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/jid.2013.526","volume":"134","author":"RR Keijsers","year":"2014","unstructured":"Keijsers RR, Hendriks AGM, van Erp PEJ, van Cranenbroek B, van de Kerkhof PCM, Koenen HJPM, et al. In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing ROR\u03b3t and IL-17. J Invest Dermatol. 2014;134(5):1276\u201384.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"483_CR26","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1111\/bjd.15533","volume":"177","author":"B Dyring-Andersen","year":"2017","unstructured":"Dyring-Andersen B, Honor\u00e9 TV, Madelung A, Bzorek M, Simonsen S, Clemmensen SN, et al. Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin. Br J Dermatol. 2017;177(6):e321\u20132.","journal-title":"Br J Dermatol"},{"key":"483_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3389\/fimmu.2018.00795","volume":"9","author":"N Tamassia","year":"2018","unstructured":"Tamassia N, Arruda-Silva F, Calzetti F, Lonardi S, Gasperini S, Gardiman E, et al. A reappraisal on the potential ability of human neutrophils to express and produce IL-17 family members in vitro: failure to reproducibly detect it. Front immunol. 2018;9:795.","journal-title":"Front immunol"},{"issue":"1","key":"483_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/bjd.14034","volume":"174","author":"A Chiricozzi","year":"2016","unstructured":"Chiricozzi A, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, Cueto I, Li K, Tian S, et al. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol. 2016;174(1):136\u201345.","journal-title":"Br J Dermatol"},{"key":"483_CR29","doi-asserted-by":"publisher","first-page":"3908061","DOI":"10.1155\/2017\/3908061","volume":"2017","author":"T Kuwabara","year":"2017","unstructured":"Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediat Inflamm. 2017;2017:3908061.","journal-title":"Mediat Inflamm"},{"issue":"2","key":"483_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/exd.13467","volume":"27","author":"JG Krueger","year":"2018","unstructured":"Krueger JG, Brunner PM. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Exp Dermatol. 2018;27(2):115\u201323.","journal-title":"Exp Dermatol"},{"issue":"13","key":"483_CR31","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1084\/jem.21213insight3","volume":"212","author":"JG Krueger","year":"2015","unstructured":"Krueger JG. An autoimmune \u201cattack\u201d on melanocytes triggers psoriasis and cellular hyperplasia. J Exp Med. 2015;212(13):2186.","journal-title":"J Exp Med"},{"issue":"11","key":"483_CR32","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/exd.13378","volume":"26","author":"J Fuentes-Duculan","year":"2017","unstructured":"Fuentes-Duculan J, Bonifacio KM, Hawkes JE, Kunjravia N, Cueto I, Li X, et al. Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active psoriasis and localized with keratinocytes, dendritic cells and other leukocytes. Exp Dermatol. 2017;26(11):1075\u201382.","journal-title":"Exp Dermatol"},{"issue":"7","key":"483_CR33","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","volume":"192","author":"S Cheuk","year":"2014","unstructured":"Cheuk S, Wik\u00e9n M, Blomqvist L, Nyl\u00e9n S, Talme T, St\u00e5hle M, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3111\u201320.","journal-title":"J Immunol"},{"issue":"11","key":"483_CR34","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1172\/JCI93396","volume":"127","author":"TR Matos","year":"2017","unstructured":"Matos TR, O\u2019Malley JT, Lowry EL, Hamm D, Kirsch IR, Robins HS, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing \u03b1\u03b2 T cell clones. J Clin Invest. 2017;127(11):4031\u201341.","journal-title":"J Clin Invest"},{"issue":"1","key":"483_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1084\/jem.20030451","volume":"199","author":"E Lee","year":"2004","unstructured":"Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125\u201330.","journal-title":"J Exp Med"},{"key":"483_CR36","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2147\/TCRM.S177127","volume":"14","author":"T Wechter","year":"2018","unstructured":"Wechter T, Cline A, Feldman SR. Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. Ther Clin Risk Manag. 2018;14:1489\u201397.","journal-title":"Ther Clin Risk Manag"},{"issue":"36","key":"483_CR37","doi-asserted-by":"publisher","first-page":"24006","DOI":"10.1074\/jbc.M109.025528","volume":"284","author":"W Liu","year":"2009","unstructured":"Liu W, Ouyang X, Yang J, Liu J, Li Q, Gu Y, et al. AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J Biol Chem. 2009;284(36):24006\u201316.","journal-title":"J Biol Chem"},{"issue":"5","key":"483_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1517\/14728222.2014.889686","volume":"18","author":"A Chiricozzi","year":"2014","unstructured":"Chiricozzi A, Saraceno R, Chimenti MS, Guttman-Yassky E, Krueger JG. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? Expert Opin Ther Targets. 2014;18(5):513\u201325.","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"483_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2040622318759282","volume":"9","author":"TC Chan","year":"2018","unstructured":"Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111\u20139.","journal-title":"Ther Adv Chronic Dis"},{"issue":"12","key":"483_CR40","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1084\/jem.20060244","volume":"203","author":"JR Chan","year":"2006","unstructured":"Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577\u201387.","journal-title":"J Exp Med"},{"issue":"6","key":"483_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2017.1292137","volume":"13","author":"L Puig","year":"2017","unstructured":"Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clinical Immunol. 2017;13(6):525\u201334.","journal-title":"Expert Rev Clinical Immunol"},{"key":"483_CR42","first-page":"75","volume":"8","author":"EJ Yang","year":"2018","unstructured":"Yang EJ, Beck KM, Liao W. Secukinumab in the treatment of psoriasis: patient selection and perspectives. Psoriasis (Auckl). 2018;8:75\u201382.","journal-title":"Psoriasis (Auckl)"},{"issue":"2","key":"483_CR43","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaad.2017.03.026","volume":"77","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Lebwohl MG, Green LJ, Hsu S, Bhatt V, et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017;77(2):372\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"483_CR44","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2147\/DDDT.S92128","volume":"11","author":"A Giunta","year":"2017","unstructured":"Giunta A, Ventura A, Chimenti MS, Bianchi L, Esposito M. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy. Drug Des Devel Ther. 2017;11:1643\u201351.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"483_CR45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40257-018-0366-5","volume":"19","author":"S Mylle","year":"2018","unstructured":"Mylle S, Grine L, Speeckaert R, Lambert JLW, van Geel N. Targeting the IL-23\/IL-17 pathway in psoriasis: the search for the good, the bad and the ugly. Am J Clin Dermatol. 2018;19(5):625\u201337.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"483_CR46","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"483_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1161\/CIRCULATIONAHA.117.029126","volume":"136","author":"D Kivelevitch","year":"2017","unstructured":"Kivelevitch D, Schussler JM, Menter A. Coronary plaque characterization in psoriasis. Circulation. 2017;136(3):277\u201380.","journal-title":"Circulation"},{"issue":"1","key":"483_CR48","doi-asserted-by":"publisher","first-page":"E58","DOI":"10.3390\/ijms19010058","volume":"19","author":"L Puig","year":"2017","unstructured":"Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci. 2017;19(1):E58.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"483_CR49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1600-0625.2011.01308.x","volume":"20","author":"AW Armstrong","year":"2011","unstructured":"Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol. 2011;20(7):544\u20139.","journal-title":"Exp Dermatol"},{"issue":"2","key":"483_CR50","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1053\/j.gastro.2016.10.018","volume":"152","author":"C Abraham","year":"2017","unstructured":"Abraham C, Dulai PS, Vermeire S, Sandborn WJ. Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):374-88.e4.","journal-title":"Gastroenterology"},{"issue":"4","key":"483_CR51","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"9993","key":"483_CR52","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"1","key":"483_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"key":"483_CR54","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2147\/DDDT.S113683","volume":"11","author":"M Roman","year":"2017","unstructured":"Roman M, Chiu MW. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;11:2065\u201375.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"483_CR55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","volume":"130","author":"JG Krueger","year":"2012","unstructured":"Krueger JG, Fretzin S, Su\u00e1rez-Fari\u00f1as M, Haslett PA, Phipps KM, Cameron GS, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145-54.e9.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"483_CR56","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","volume":"35","author":"Y Cai","year":"2011","unstructured":"Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity. 2011;35(4):596\u2013610.","journal-title":"Immunity"},{"issue":"2","key":"483_CR57","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/13543784.2017.1274734","volume":"26","author":"ZZ Yiu","year":"2017","unstructured":"Yiu ZZ, Warren RB. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. Expert Opin Investig Drugs. 2017;26(2):243\u20139.","journal-title":"Expert Opin Investig Drugs"},{"issue":"10148","key":"483_CR58","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361.","journal-title":"Lancet"},{"issue":"2","key":"483_CR59","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/511051","volume":"80","author":"M Cargill","year":"2007","unstructured":"Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273\u201390.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"483_CR60","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"483_CR61","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-9.e9.","journal-title":"J Am Acad Dermatol"},{"key":"483_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/OARRR.S56073","volume":"9","author":"S D'Angelo","year":"2017","unstructured":"D\u2019Angelo S, Tramontano G, Gilio M, Leccese P, Olivieri I. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol. 2017;9:21\u20138.","journal-title":"Open Access Rheumatol"},{"key":"483_CR63","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","volume":"68","author":"J Kim","year":"2017","unstructured":"Kim J, Krueger JG. Highly effective new treatments for psoriasis target the IL-23\/type 17 T cell autoimmune axis. Ann Rev Med. 2017;68:255\u201369.","journal-title":"Ann Rev Med"},{"issue":"2","key":"483_CR64","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","volume":"79","author":"KA Papp","year":"2018","unstructured":"Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277-86.e10.","journal-title":"J Am Acad Dermatol"},{"issue":"10222","key":"483_CR65","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","volume":"395","author":"CT Ritchlin","year":"2020","unstructured":"Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427\u201340.","journal-title":"Lancet"},{"issue":"1","key":"483_CR66","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjd.17628","volume":"181","author":"K Reich","year":"2019","unstructured":"Reich K, Rich P, Maari C, Bissonnette R, Leonardi C, Menter A, et al. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol. 2019;181(1):88\u201395.","journal-title":"Br J Dermatol"},{"issue":"3","key":"483_CR67","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020;158(3):537-49.e10.","journal-title":"Gastroenterology"},{"issue":"6","key":"483_CR68","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/S0016-5085(19)37335-4","volume":"156","author":"B Sands","year":"2019","unstructured":"Sands B, Sandborn W, Peyrin-Biroulet L, Higgins P, Hirai F, Belin R, et al. 1003 Efficacy and safety of mirikizumab (LY3074828) in a phase 2 study of patients with crohn\u2019s disease. Gastroenterology. 2019;156(6):S216.","journal-title":"Gastroenterology"},{"issue":"5","key":"483_CR69","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, Khraishi MM, Tha\u00e7i D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729\u201335.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"483_CR70","first-page":"14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):14\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"483_CR71","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"483_CR72","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851\u201364.","journal-title":"J Am Acad Dermatol"},{"issue":"1\u20132","key":"483_CR73","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","volume":"359","author":"SP Raychaudhuri","year":"2012","unstructured":"Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1\u20132):419\u201329.","journal-title":"Mol Cell Biochem"},{"issue":"4\u20135","key":"483_CR74","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"13","author":"E Suzuki","year":"2014","unstructured":"Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23\/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13(4\u20135):496\u2013502.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"483_CR75","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/jcb.22326","volume":"108","author":"T Yago","year":"2009","unstructured":"Yago T, Nanke Y, Ichikawa N, Kobashigawa T, Mogi M, Kamatani N, et al. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem. 2009;108(4):947\u201355.","journal-title":"J Cell Biochem"},{"issue":"6","key":"483_CR76","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1136\/annrheumdis-2013-204782","volume":"74","author":"IE Adamopoulos","year":"2015","unstructured":"Adamopoulos IE, Suzuki E, Chao CC, Gorman D, Adda S, Maverakis E, et al. IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1284\u201392.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"483_CR77","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/jid.2014.426","volume":"135","author":"M Yamamoto","year":"2015","unstructured":"Yamamoto M, Nakajima K, Takaishi M, Kitaba S, Magata Y, Kataoka S, et al. Psoriatic inflammation facilitates the onset of arthritis in a mouse model. J Invest Dermatol. 2015;135(2):445\u201353.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"483_CR78","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1172\/JCI5703","volume":"103","author":"S Kotake","year":"1999","unstructured":"Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103(9):1345\u201352.","journal-title":"J Clin Invest"},{"issue":"1","key":"483_CR79","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/ar2936","volume":"12","author":"IE Adamopoulos","year":"2010","unstructured":"Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, et al. Interleukin-17A upregulates receptor activator of NF-\u03baB on osteoclast precursors. Arthritis Res Ther. 2010;12(1):R29.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"483_CR80","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13075-017-1249-5","volume":"19","author":"SP Raychaudhuri","year":"2017","unstructured":"Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Res Ther. 2017;19(1):51.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"483_CR81","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4049\/jimmunol.1401013","volume":"194","author":"HS Shin","year":"2015","unstructured":"Shin HS, Sarin R, Dixit N, Wu J, Gershwin E, Bowman EP, et al. Crosstalk among IL-23 and DNAX activating protein of 12 kDa-dependent pathways promotes osteoclastogenesis. J Immunol. 2015;194(1):316\u201324.","journal-title":"J Immunol"},{"issue":"2","key":"483_CR82","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/BOR.0000000000000155","volume":"27","author":"EL Siegel","year":"2015","unstructured":"Siegel EL, Orbai AM, Ritchlin CT. Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis. Curr Opin Rheumatol. 2015;27(2):111\u20137.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"483_CR83","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/jid.2012.194","volume":"133","author":"DA Martin","year":"2013","unstructured":"Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17\u201326.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"483_CR84","doi-asserted-by":"publisher","first-page":"272","DOI":"10.5152\/eurjrheum.2017.17037","volume":"4","author":"EA Wang","year":"2017","unstructured":"Wang EA, Suzuki E, Maverakis E, Adamopoulos IE. Targeting IL-17 in psoriatic arthritis. Eur J Rheumatol. 2017;4(4):272\u20137.","journal-title":"Eur J Rheumatol"},{"issue":"6","key":"483_CR85","first-page":"890","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landew\u00e9 R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"9999","key":"483_CR86","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"14","key":"483_CR87","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"issue":"10086","key":"483_CR88","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317\u201327.","journal-title":"Lancet"},{"issue":"1","key":"483_CR89","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331.","journal-title":"Ann Rheum Dis"},{"key":"483_CR90","unstructured":"European Medicines Agency. Cosentyx [summary of product characteristics]. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf. Accessed 24 Oct 2019."},{"key":"483_CR91","unstructured":"European Medicines Agency. Talz [summary of product characteristics]. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/taltz-epar-product-information_en.pdf. Accessed 24 Oct 2019."},{"issue":"10230","key":"483_CR92","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"10230","key":"483_CR93","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336.","journal-title":"Lancet"},{"issue":"8","key":"483_CR94","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","volume":"79","author":"K McKeage","year":"2019","unstructured":"McKeage K, Duggan S. Risankizumab: first global approval. Drugs. 2019;79(8):893\u2013900.","journal-title":"Drugs"},{"issue":"8","key":"483_CR95","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial. J Dermatol. 2019;46(8):686\u201394.","journal-title":"J Dermatol"},{"key":"483_CR96","unstructured":"Humira\u00ae (adalimumab) [package insert]. Chicago, IL: AbbVie, Inc; 2020."},{"key":"483_CR97","unstructured":"Enbrel\u00ae (etanercept) [package insert].\u00a0Thousand Oaks, CA: Immunex Corporation; 2020."},{"key":"483_CR98","unstructured":"Taltz\u00ae (ixekizumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020."},{"key":"483_CR99","unstructured":"Tremfya\u00ae (guselkumab) [package insert].\u00a0Horsham, PA: Janssen Biotech, Inc; 2020."},{"key":"483_CR100","unstructured":"Cosentyx\u00ae (secukinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020."},{"issue":"7","key":"483_CR101","first-page":"695","volume":"16","author":"MH Henderson Berg","year":"2017","unstructured":"Henderson Berg MH, Carrasco D. Injection site reactions to biologic agents used in psoriasis and psoriatic arthritis. J Drugs Dermatol. 2017;16(7):695\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"483_CR102","doi-asserted-by":"publisher","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","volume":"2","author":"EJ Armstrong","year":"2013","unstructured":"Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"483_CR103","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1001\/jamadermatol.2016.2907","volume":"152","author":"B Mansouri","year":"2016","unstructured":"Mansouri B, Kivelevitch D, Natarajan B, Joshi AA, Ryan C, Benjegerdes K, et al. Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes. JAMA Dermatol. 2016;152(11):1244\u201353.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"483_CR104","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","volume":"31","author":"NN Mehta","year":"2010","unstructured":"Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000\u20136.","journal-title":"Eur Heart J"},{"issue":"7","key":"483_CR105","doi-asserted-by":"publisher","first-page":"e0181039","DOI":"10.1371\/journal.pone.0181039","volume":"12","author":"S Singh","year":"2017","unstructured":"Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: a meta-analysis of observational studies. PLoS ONE. 2017;12(7):e0181039.","journal-title":"PLoS ONE"},{"key":"483_CR106","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/1479-5876-11-194","volume":"11","author":"NN Mehta","year":"2013","unstructured":"Mehta NN, Li K, Szapary P, Krueger J, Brodmerkel C. Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. J Transl Med. 2013;11:194.","journal-title":"J Transl Med"},{"issue":"12","key":"483_CR107","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.amjmed.2014.08.008","volume":"127","author":"J Shlyankevich","year":"2014","unstructured":"Shlyankevich J, Mehta NN, Krueger JG, Strober B, Gudjonsson JE, Qureshi AA, et al. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. Am J Med. 2014;127(12):1148\u201353.","journal-title":"Am J Med"},{"issue":"2","key":"483_CR108","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1161\/ATVBAHA.114.303567","volume":"35","author":"S Taleb","year":"2015","unstructured":"Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol. 2015;35(2):258\u201364.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"483_CR109","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1038\/jid.2012.112","volume":"132","author":"Y Wang","year":"2012","unstructured":"Wang Y, Gao H, Loyd CM, Fu W, Diaconu D, Liu S, et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol. 2012;132(8):2067\u201375.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"483_CR110","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jid.2017.09.021","volume":"138","author":"Y Li","year":"2018","unstructured":"Li Y, Golden JB, Camhi MI, Zhang X, Fritz Y, Diaconu D, et al. Protection from psoriasis-related thrombosis after inhibition of IL-23 or IL-17A. J Invest Dermatol. 2018;138(2):310\u20135.","journal-title":"J Invest Dermatol"},{"issue":"20","key":"483_CR111","doi-asserted-by":"publisher","first-page":"e89384","DOI":"10.1172\/jci.insight.89384","volume":"1","author":"Y Wang","year":"2016","unstructured":"Wang Y, Golden JB, Fritz Y, Zhang X, Diaconu D, Camhi MI, et al. Interleukin 6 regulates psoriasiform inflammation-associated thrombosis. JCI Insight. 2016;1(20):e89384.","journal-title":"JCI Insight"},{"issue":"9","key":"483_CR112","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1161\/CIRCRESAHA.110.221069","volume":"107","author":"ML Dart","year":"2010","unstructured":"Dart ML, Jankowska-Gan E, Huang G, Roenneburg DA, Keller MR, Torrealba JR, et al. Interleukin-17-dependent autoimmunity to collagen type V in atherosclerosis. Circ Res. 2010;107(9):1106\u201316.","journal-title":"Circ Res"},{"issue":"1","key":"483_CR113","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2013.11.021","volume":"40","author":"H Lim","year":"2014","unstructured":"Lim H, Kim YU, Sun H, Lee JH, Reynolds JM, Hanabuchi S, et al. Proatherogenic conditions promote autoimmune T helper 17 cell responses in vivo. Immunity. 2014;40(1):153\u201365.","journal-title":"Immunity"},{"issue":"5","key":"483_CR114","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1681\/ASN.2008050556","volume":"20","author":"HJ Paust","year":"2009","unstructured":"Paust HJ, Turner JE, Steinmetz OM, Peters A, Heymann F, H\u00f6lscher C, et al. The IL-23\/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol. 2009;20(5):969\u201379.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"483_CR115","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.109.145094","volume":"55","author":"MS Madhur","year":"2010","unstructured":"Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, et al. Interleukin 17 promotes angiotensin ii\u2013induced hypertension and vascular dysfunction. Hypertension. 2010;55(2):500\u20137.","journal-title":"Hypertension"},{"issue":"2","key":"483_CR116","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1681\/ASN.2010050536","volume":"22","author":"AR Kitching","year":"2011","unstructured":"Kitching AR, Holdsworth SR. The emergence of TH17 cells as effectors of renal injury. Am Soc Nephrol. 2011;22(2):235\u20138.","journal-title":"Am Soc Nephrol"},{"issue":"6","key":"483_CR117","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.116.303697","volume":"116","author":"WG McMaster","year":"2015","unstructured":"McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end-organ damage. Circ Res. 2015;116(6):1022\u201333.","journal-title":"Circ Res"},{"issue":"1","key":"483_CR118","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaad.2015.03.041","volume":"73","author":"G Varricchi","year":"2015","unstructured":"Varricchi G, Granata F, Loffredo S, Genovese A, Marone G. Angiogenesis and lymphangiogenesis in inflammatory skin disorders. J Am Acad Dermatol. 2015;73(1):144\u201353.","journal-title":"J Am Acad Dermatol"},{"key":"483_CR119","unstructured":"Krueger J, Pariser D, Lee P, Bagel J, Armstrong A, Muscianisi E, et al. Secukinumab treatment normalizes inflammatory markers and immune response and leads to clinical improvement in patients with psoriasis: findings from the primary analysis of the ObePso-S study [abstract]. 24th World Congress of Dermatology, Milan, Italy 10\u201315 June, 2019."},{"issue":"6","key":"483_CR120","doi-asserted-by":"publisher","first-page":"e007394","DOI":"10.1161\/CIRCIMAGING.117.007394","volume":"11","author":"NN Mehta","year":"2018","unstructured":"Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial. Circ Cardiovasc Imaging. 2018;11(6):e007394.","journal-title":"Circ Cardiovasc Imaging"},{"key":"483_CR121","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jim-2018-000730","volume":"66","author":"JM Gelfand","year":"2018","unstructured":"Gelfand JM, Takeshita J, Dey A, Shin D, Noe M, Fuxench ZC, et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial). J Investig Med. 2018;66:697.","journal-title":"J Investig Med"},{"issue":"1","key":"483_CR122","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Shin DB, Alavi A, Torigian DA, Werner T, Papadopoulos M, et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial). J Invest Dermatol. 2020;140(1):85-93.e2.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"483_CR123","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Shin DB, Duffin KC, Armstrong AW, Blauvelt A, Tyring SK, et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Invest Dermatol. 2020;140(9):1784-93.e2.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"483_CR124","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/art.38291","volume":"66","author":"JA Smith","year":"2014","unstructured":"Smith JA, Colbert RA. Review: The interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol. 2014;66(2):231\u201341.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"483_CR125","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/BOR.0000000000000301","volume":"28","author":"A Paine","year":"2016","unstructured":"Paine A, Ritchlin CT. Targeting the interleukin-23\/17 axis in axial spondyloarthritis. Curr Opin Rheumatol. 2016;28(4):359\u201367.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"483_CR126","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","volume":"14","author":"J Feld","year":"2018","unstructured":"Feld J, Chandran V, Haroon N, Inman R, Gladman D. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol. 2018;14(6):363\u201371.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"483_CR127","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/cei.12670","volume":"183","author":"H Jethwa","year":"2016","unstructured":"Jethwa H, Bowness P. The interleukin (IL)-23\/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment. Clin Exp Immunol. 2016;183(1):30\u20136.","journal-title":"Clin Exp Immunol"},{"issue":"26","key":"483_CR128","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor. Ankyl Spondylitis N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"Ankyl Spondylitis N Engl J Med"},{"issue":"4","key":"483_CR129","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599\u2013611.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"483_CR130","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","volume":"79","author":"M Dougados","year":"2020","unstructured":"Dougados M, Wei JC, Landew\u00e9 R, Sieper J, Baraliakos X, Van den Bosch F, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176\u201385.","journal-title":"Ann Rheum Dis"},{"key":"483_CR131","doi-asserted-by":"crossref","unstructured":"Braun J, Blanco R, Dokoupilova E, Gensler LS, Kivitz A, Hall S, et al. Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase III PREVENT study. Presented at: EULAR 2020; June 3\u20136, 2020:Abstract OP0106.","DOI":"10.1136\/annrheumdis-2020-eular.598"},{"issue":"10217","key":"483_CR132","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, \u00d8stergaard M, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53\u201364.","journal-title":"Lancet"},{"issue":"9","key":"483_CR133","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, \u00d8stergaard M, Wei JC, Sieper J, Jarvinen P, Tam LS, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295\u2013302.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"483_CR134","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1097\/MIB.0000000000001169","volume":"23","author":"H Eppinga","year":"2017","unstructured":"Eppinga H, Poortinga S, Thio HB, Nijsten TEC, Nuij VJAA, van der Woude CJ, et al. Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(10):1783\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"483_CR135","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jaad.2016.10.027","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"483_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2018.12.002","volume":"45","author":"MF Neurath","year":"2019","unstructured":"Neurath MF. IL-23 in inflammatory bowel diseases and colon cancer. Cytokine Growth Factor Rev. 2019;45:1\u20138.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"483_CR137","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","volume":"78","author":"S Schreiber","year":"2019","unstructured":"Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78(4):473\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"483_CR138","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","volume":"53","author":"B Verstockt","year":"2018","unstructured":"Verstockt B, Ferrante M, Vermeire S, Van Assche G. New treatment options for inflammatory bowel diseases. J Gastroenterol. 2018;53(5):585\u201390.","journal-title":"J Gastroenterol"},{"issue":"10","key":"483_CR139","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","volume":"3","author":"BG Feagan","year":"2018","unstructured":"Feagan BG, Panes J, Ferrante M, Kaser A, D\u2019Haens GR, Sandborn WJ, et al. Risankizumab in patients with moderate to severe Crohn\u2019s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3(10):671\u201380.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"483_CR140","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700.","journal-title":"Gut"},{"issue":"11","key":"483_CR141","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"SR Targan","year":"2016","unstructured":"Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol. 2016;111(11):1599\u2013607.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"483_CR142","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12876-019-1067-0","volume":"19","author":"MK Smith","year":"2019","unstructured":"Smith MK, Pai J, Panaccione R, Beck P, Ferraz JG, Jijon H. Crohn\u2019s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol. 2019;19(1):162.","journal-title":"BMC Gastroenterol"},{"issue":"14","key":"483_CR143","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328.","journal-title":"N Engl J Med"},{"issue":"5","key":"483_CR144","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaad.2018.05.032","volume":"79","author":"C Leonardi","year":"2018","unstructured":"Leonardi C, Maari C, Philipp S, Goldblum O, Zhang L, Burkhardt N, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79(5):824-30.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"483_CR145","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","volume":"154","author":"P Foley","year":"2018","unstructured":"Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. JAMA Dermatol. 2018;154(6):676\u201383.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"483_CR146","first-page":"S12","volume":"9","author":"AW Armstrong","year":"2016","unstructured":"Armstrong AW, Vender R, Kircik L. Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis. J Clin Aesthet Dermatol. 2016;9(6):S12\u20136.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"483_CR147","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","volume":"76","author":"A Gottlieb","year":"2017","unstructured":"Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"483_CR148","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jdv.14237","volume":"31","author":"A Menter","year":"2017","unstructured":"Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31(10):1686\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"483_CR149","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.16736","volume":"179","author":"C Ryan","year":"2018","unstructured":"Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179(4):844\u201352.","journal-title":"Br J Dermatol"},{"issue":"1","key":"483_CR150","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaad.2018.01.003","volume":"79","author":"JR Georgakopoulos","year":"2018","unstructured":"Georgakopoulos JR, Phung M, Ighani A, Yeung J. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol. 2018;79(1):155\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"483_CR151","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/09546634.2018.1506081","volume":"30","author":"T Bokor-Billmann","year":"2019","unstructured":"Bokor-Billmann T, Sch\u00e4kel K. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. J Dermatolog Treat. 2019;30(3):216\u201320.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"483_CR152","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/09546634.2017.1422591","volume":"29","author":"J Bilal","year":"2018","unstructured":"Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatol Treat. 2018;29(6):569\u201378.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"483_CR153","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/1346-8138.14096","volume":"45","author":"M Kamata","year":"2018","unstructured":"Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018;45(3):279\u201386.","journal-title":"J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00483-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T03:04:11Z","timestamp":1667012651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00483-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":153,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["483"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00483-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"1 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}